YAP augments PD-L1 expression in EGFR inhibitor-resistant lung cancer [73,74], pancreatic cancer [75], mesothelioma [76] and BRAF inhibitor-resistant melanoma [77]. This evidence concerns the gene BRAF and melanoma.